CVS Health Corporation $CVS Holdings Lifted by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its position in CVS Health Corporation (NYSE:CVS) by 3.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 166,163 shares of the pharmacy operator’s stock after purchasing an additional 5,237 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in CVS Health were worth $12,045,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp lifted its stake in shares of CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after acquiring an additional 1,245,457 shares during the period. Fort Washington Investment Advisors Inc. OH increased its stake in shares of CVS Health by 2.9% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 725,189 shares of the pharmacy operator’s stock valued at $57,551,000 after acquiring an additional 20,217 shares during the period. Legal & General Group Plc increased its stake in shares of CVS Health by 0.3% during the fourth quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock valued at $738,777,000 after acquiring an additional 31,249 shares during the period. Deutsche Bank AG raised its holdings in CVS Health by 28.4% during the fourth quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock worth $370,333,000 after purchasing an additional 1,031,998 shares in the last quarter. Finally, KBC Group NV lifted its position in CVS Health by 200.4% in the fourth quarter. KBC Group NV now owns 676,809 shares of the pharmacy operator’s stock worth $53,711,000 after purchasing an additional 451,521 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS announced that common prescription medications for dogs and cats are now available at its roughly 9,000 CVS Pharmacy locations nationwide, expanding the chain’s role beyond human prescriptions and potentially adding a small but incremental revenue stream while increasing store traffic. Pet medications now available at CVS Pharmacy®
• Positive Sentiment: Market commentary highlighted that CVS has been outperforming the broader market, reflecting continued investor confidence in the company’s ongoing operational improvement and turnaround efforts. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Positive Sentiment: Another report echoed the same outperformance theme, noting CVS’s strong trading versus the market and suggesting that investors remain focused on the company’s improving fundamentals. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Neutral Sentiment: A longer-form analysis argued CVS is still in the middle of a meaningful turnaround, with improving margins, declining leverage, and strong cash flow, but it also noted the stock is no longer viewed as a deep bargain after its rally. CVS Health Update: The C- Student Now Pulling Down A B+

CVS Health Trading Up 2.6%

NYSE:CVS opened at $110.40 on Wednesday. The stock has a fifty day simple moving average of $99.58 and a 200 day simple moving average of $85.58. The firm has a market capitalization of $140.87 billion, a price-to-earnings ratio of 48.64, a price-to-earnings-growth ratio of 1.05 and a beta of 0.61. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $110.62. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the previous year, the company earned $2.25 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts forecast that CVS Health Corporation will post 7.46 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be given a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.4%. CVS Health’s payout ratio is presently 117.18%.

Insiders Place Their Bets

In other news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. The trade was a 7.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last three months. Company insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on CVS. Sanford C. Bernstein boosted their price objective on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 12th. Piper Sandler reaffirmed an “overweight” rating and set a $113.00 target price on shares of CVS Health in a report on Monday, June 1st. Robert W. Baird boosted their price target on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Mizuho raised their price objective on shares of CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Finally, Wells Fargo & Company lifted their price objective on shares of CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Twenty-one investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $105.38.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.